Lexon shared sensitive market data to halt drug-price fall, CMA tells UK antitrust court
Lexon was rightly fined by UK antitrust enforcers after it shared sensitive drug-market information with rivals at a time of heightened competition and falling prices of an antidepressant medicine, the Competition...To view the full article, register now.
Already a subscriber? Click here to view full article